Aptose Biosciences Inc - Asset Resilience Ratio
Aptose Biosciences Inc (APS) has an Asset Resilience Ratio of 15.49% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check APS capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1996–2023)
This chart shows how Aptose Biosciences Inc's Asset Resilience Ratio has changed over time. See APS net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Aptose Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Aptose Biosciences Inc worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$1.98 Million | 15.49% |
| Total Liquid Assets | CA$1.98 Million | 15.49% |
Asset Resilience Insights
- Good Liquidity Position: Aptose Biosciences Inc maintains a healthy 15.49% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Aptose Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Aptose Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Aptose Biosciences Inc (1996–2023)
The table below shows the annual Asset Resilience Ratio data for Aptose Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | CA$0.00 ≈ $0.00 |
CA$12.99 Million ≈ $9.40 Million |
-- |
| 2022-12-31 | 90.86% | CA$46.36 Million ≈ $33.54 Million |
CA$51.03 Million ≈ $36.91 Million |
-4.67pp |
| 2021-12-31 | 95.53% | CA$78.83 Million ≈ $57.03 Million |
CA$82.53 Million ≈ $59.70 Million |
-1.15pp |
| 2020-12-31 | 96.68% | CA$122.06 Million ≈ $88.30 Million |
CA$126.26 Million ≈ $91.34 Million |
+1.17pp |
| 2019-12-31 | 95.51% | CA$95.96 Million ≈ $69.42 Million |
CA$100.48 Million ≈ $72.68 Million |
+5.89pp |
| 2018-12-31 | 89.61% | CA$15.12 Million ≈ $10.94 Million |
CA$16.87 Million ≈ $12.20 Million |
-5.89pp |
| 2017-12-31 | 95.50% | CA$11.43 Million ≈ $8.27 Million |
CA$11.97 Million ≈ $8.66 Million |
+3.67pp |
| 2016-12-31 | 91.83% | CA$7.94 Million ≈ $5.74 Million |
CA$8.65 Million ≈ $6.25 Million |
+53.03pp |
| 2015-12-31 | 38.80% | CA$5.96 Million ≈ $4.31 Million |
CA$15.35 Million ≈ $11.11 Million |
-12.40pp |
| 2014-12-31 | 51.20% | CA$13.97 Million ≈ $10.11 Million |
CA$27.29 Million ≈ $19.74 Million |
+40.48pp |
| 2010-12-31 | 10.73% | CA$234.10K ≈ $169.34K |
CA$2.18 Million ≈ $1.58 Million |
+4.22pp |
| 2009-12-31 | 6.51% | CA$449.54K ≈ $325.19K |
CA$6.91 Million ≈ $5.00 Million |
-51.94pp |
| 2008-12-31 | 58.45% | CA$6.82 Million ≈ $4.94 Million |
CA$11.67 Million ≈ $8.44 Million |
+11.50pp |
| 2007-12-31 | 46.94% | CA$6.79 Million ≈ $4.91 Million |
CA$14.47 Million ≈ $10.47 Million |
-2.15pp |
| 2006-12-31 | 49.09% | CA$5.11 Million ≈ $3.70 Million |
CA$10.41 Million ≈ $7.53 Million |
-18.68pp |
| 2005-12-31 | 67.77% | CA$14.89 Million ≈ $10.77 Million |
CA$21.97 Million ≈ $15.89 Million |
0.00pp |
| 2004-12-31 | 67.77% | CA$14.89 Million ≈ $10.77 Million |
CA$21.97 Million ≈ $15.89 Million |
-6.76pp |
| 2003-12-31 | 74.53% | CA$18.83 Million ≈ $13.62 Million |
CA$25.27 Million ≈ $18.28 Million |
-2.52pp |
| 2002-12-31 | 77.06% | CA$23.99 Million ≈ $17.35 Million |
CA$31.13 Million ≈ $22.52 Million |
+0.00pp |
| 2001-12-31 | 77.06% | CA$23.99 Million ≈ $17.35 Million |
CA$31.13 Million ≈ $22.52 Million |
+2.58pp |
| 2000-12-31 | 74.48% | CA$29.94 Million ≈ $21.66 Million |
CA$40.20 Million ≈ $29.08 Million |
+66.66pp |
| 1999-12-31 | 7.82% | CA$3.78 Million ≈ $2.73 Million |
CA$48.30 Million ≈ $34.94 Million |
-43.03pp |
| 1997-12-31 | 50.85% | CA$2.06 Million ≈ $1.49 Million |
CA$4.05 Million ≈ $2.93 Million |
-22.74pp |
| 1996-12-31 | 73.58% | CA$5.66 Million ≈ $4.09 Million |
CA$7.69 Million ≈ $5.56 Million |
-- |
About Aptose Biosciences Inc
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloi… Read more